Due to a huge increase in living standards, coupled with a steadily growing and increasingly affluent population, the South East Asian pharma market is now one of the most diverse and rapidly changing regions in the world.
Association of South East Asian Nations (ASEAN) pharma industry is projected to have a combined market value of US$ 80 billion by 2017. The favourable government policies, business strategies and shifts in consumer trends are fast changing the market dynamics of the region.
These changes are set to accelerate over the next few years with the planned harmonisation across ASEAN which comprise Malaysia, Burma, the Philippines, Singapore, Thailand, Vietnam, Brunei, Cambodia, Indonesia, Laos - due for completion in 2015. The ASEAN will enable an integrated regulatory region similar to those present within the US and Europe.
Furthermore, the evolving and diverse regulatory landscape across the region, and the complexity associated with individual countries will make harmonisation an ambitious, but challenging goal. It is therefore now more crucial than ever for the pharmaceutical industry across the entire value chain to keep updated with the evolving regulatory arena and initiatives led by governments and industry in the region.
In this context CPhI South East Asia, one of the premium exhibitions related to pharmaceutical ingredients being held from March 20 to 22, 2013 at Jakarta International Expo, Indonesia is of special significance.
CPhI SEA brings together key decision makers and high-quality pharma ingredients suppliers from ASEAN countries and all around the world giving direct access to the heart of the fast-growing ASEAN pharma markets. It helps to expand exhibitor and visitor networks in the local
ASEAN pharma market through a unique platform that facilitates face to face discussions that otherwise may not happen.
"Highlights of CPhI South East Asia 2013 includes a Pharmaceutical Summit – a high level conference presenting first class speakers with most qualified expertise, covering important topics in the industry, a seminar by USAID and US Pharmacopeial on WHO Pre-Qualification focusing on TB, and Technology Talk presented by Exhibitors daily", says Martin Wilson, Event Manager, UBM Live.
"This year, CPhI South East Asia brings two more of the CPhI brands to this edition : InnoPack for packaging solutions and PMEC for machinery and equipment. These two new sections are co-located with CPhI South East Asia for visitors to see a complete range of production chain under one roof. In addition, the size of the event has also grown by 30 per cent, and with the concurrent Pharmaceutical Summit, it is going to present a gathering of top level pharma professionals in this region during this three-day day event" he adds.
The addition of P-MEC serves to highlight the growth of the finished dosage and generics sectors, which is currently being driven by rapid growth in the manufacture base of South East Asia. The introduction of InnoPack will further extend the scope of the event by bringing a focus to the important role that packaging plays in product development, safety, dosage and dispensing.
This year’s event will feature an increased offering of learning summit and training workshops along with two additional co-located industry events. The visitors would be able to meet the key decision makers and role players. A major focus of the event is the innovation award which showcases the latest discovery in the field of pharmaceuticals.
"We have over 250 exhibitors this year, and 41 of them are from India. We are expecting about 7,000 visitors this year" , he says.
With the significant regional and ambitious changes in the region , this year's CPhI South East Asia event is focusing at the potential effects of harmonisation, both in terms of country-by-country growth rates and regulatory changes for pharma sector firms.
The global CPhI portfolio centres on driving growth and innovation across the diverse sectors of the pharmaceutical industry. As part of this initiative, CPhI South East Asia debuted last year to highlight the vibrant ASEAN market and offer attendees and exhibitors direct access to a region with strong government support for pharmaceutical production, a large population of prospective customers and a dynamic and growing economy.
The CPhI South East Asia Pharmaceutical Summit for 2013 will be giving the latest market insights with in-depth dialogues from global and local practitioners. The high-level summit programme being held from March 20 to 21 offers exceptional networking opportunities and discussions on ASEAN harmonisation, trade and border regulations, the contract services industry in South East Asia and a local healthcare perspective with a full view into the pharmerging markets.
"The location in Indonesia is unique, as it offers a first hand look into the ongoing harmonisation happening across the ASEAN region. Indonesia is currently the world’s fourth most populous country with around 238 million people and a CAGR of 11 per cent, which is well above the world’s average. This is a market that can bring significant benefits to our customer base, with CPhI South East Asia providing a unique opportunity to engage with industry leaders and decision makers from the region. We are pleased that the event was such a success in its first year with 220 exhibitors and 4,500 attendees, and we look forward to providing another focused, innovative event in a region that is actively building up infrastructure and encouraging foreign investment to our attendees and exhibitors in 2013", says Martin Wilson..
The 2013 return of CPhI South East Asia, with the addition of P-MEC and InnoPack will offer an effective venue for pharma professionals to make valuable business connections and maximise ROI both in South East Asia and across the globe. Beyond the strong growth in Indonesia, Vietnam’s pharma industry is expected to have a CAGR of 24 per cent, with Malaysia and other countries in the region also poised for growth. According to the Indonesian Pharmaceutical Association, the sales figure of pharmaceutical market in Indonesia alone will reach US$5.7 billion this year with a projected growth of between 12 to 15 per cent
CPhI South East Asia was launched in 2012 as an extension of the worldwide leading event for the pharmaceutical ingredients : CPhI, to serve the South East Asia region with more focus. South East Asia is a region with high growth and great potential. The total population is about 560 million people with developing healthcare access and consequently needs for medicine also rises creating a huge opportunity for the pharmaceutical industry.
"Indonesia is chosen as the host country for the first launch and the second edition this year; given the fact that it is the largest economy in South East Asia, one of the top three market for pharmaceutical products in the region, importing over 95 per cent of its ingredients for production and the new social security programme from the government to provide free healthcare for additional 76 million people beginning in 2014. CPhI South East Asia bridges the buyers and sellers, providing sourcing channel for pharma manufacturers in finding good and reliable suppliers and establishing business contacts for suppliers who are seeking to expand their market in this region" points out Martin Wilson.